- Home
- HOWL
as 12-27-2024 4:00pm EST
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 87.4M | IPO Year: | 2021 |
| Target Price: | $13.50 | AVG Volume (30 days): | 344.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $8.19 | Next Earning Date: | 11-07-2024 |
| Revenue: | $3,386,000 | Revenue Growth: | -86.84% |
| Revenue Growth (this year): | -90.39% | Revenue Growth (next year): | 34.17% |
Latest Werewolf Therapeutics Inc. News
HOWL Breaking Stock News: Dive into HOWL Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
GlobeNewswire
2 months ago
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
GlobeNewswire
2 months ago
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
TipRanks
2 months ago
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
3 months ago
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
GlobeNewswire
4 months ago
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
MT Newswires
5 months ago
Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating
Compare HOWL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOWL Werewolf Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.